Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Structure TherapeuticsGPCR -1.14%30 6-1 Month Momentum % is -24.14% as of Aug. 27, 2026. GuruFocus rates GPCR with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,376 Biotechnology companies, Structure Therapeutics ranks worse than 58.28% on this metric.
6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2026-08-27), Structure Therapeutics's 6-1 Month Momentum % is -24.14%.
The industry rank for Structure Therapeutics's 6-1 Month Momentum % or its related term are showing as below:
GPCR's 6-1 Month Momentum % is ranked worse than 58.28% of 1376
companies
in the Biotechnology industry
Industry Median: -16.5
vs GPCR: -24.14
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Structure Therapeutics 6-1 Month Momentum % Related Terms
GPCR vs NAMS, ARQT, ALMS: 6-1 Month Momentum % Comparison
For the Biotechnology subindustry, Structure Therapeutics's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Structure Therapeutics 6-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Structure Therapeutics's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Structure Therapeutics's 6-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Structure Therapeutics (GPCR) has a 6-1 Month Momentum % of -24.14% as of Aug. 27, 2026. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Structure Therapeutics and its competitors. According to the industry distribution chart, Structure Therapeutics ranks #802 out of 1376 companies in the Biotechnology industry, placing it in the top 58.3%.
Is Structure Therapeutics' 6-1 Month Momentum % too high?
Structure Therapeutics' current 6-1 Month Momentum % is -24.14%. Based on the distribution chart, Structure Therapeutics ranks #802 out of 1376 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Structure Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Structure Therapeutics' 6-1 Month Momentum % compare to NAMS and ARQT?
According to the Biotechnology industry distribution chart, Structure Therapeutics ranks #802 out of 1376 companies for 6-1 Month Momentum %. This places Structure Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-1 Month Momentum % for a Biotechnology company?
A good 6-1 Month Momentum % depends on the Biotechnology industry context. However, 6-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-1 Month Momentum % mean?
A high 6-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Structure Therapeutics and its competitors. Structure Therapeutics's current 6-1 Month Momentum % is -24.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Structure Therapeutics stock overvalued right now?
Structure Therapeutics (GPCR) has a current 6-1 Month Momentum % of -24.14%. The current 6-1 Month Momentum % is -24.14%. Structure Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-1 Month Momentum % calculated?
6-1 Month Momentum % is calculated from a company's financial statements. For Structure Therapeutics (GPCR), the current 6-1 Month Momentum % is -24.14% as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
30GF Score
Get the complete analysis for GPCR
6-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GPCR has been successfully added to your 
